Some of the world's best scientific brains were gearing up for the American Academy of Neurology meeting this week in Toronto, and among the hoped-for data to tumble out of sessions are details of Biogen Idec Inc.'s approach to using an iffy but promising method of weeding out likely PML cases from multiple sclerosis patients. Read More